Table 4.
In-vitro antibacterial activities of compounds (4a-p) and (5a-o).
| Compound | Minimum inhibitory concentration (MIC µg/mL) | ||||||
|---|---|---|---|---|---|---|---|
| E. coli | A. baumannii | S.aureus | MRSA | C. albicans | |||
| 4a | >500 | 500< | 349.34 | 349.34 | >500 | ||
| 4b | >500 | >500 | 4.67 | >500 | >500 | ||
| 4c | 341.36 | >500 | >500 | >500 | >500 | ||
| 4d | >500 | >500 | >500 | >500 | >500 | ||
| 4e | >500 | >500 | 297.27 | >500 | >500 | ||
| 4f | >500 | >500 | 363.37 | 363.37 | >500 | ||
| 4g | >500 | >500 | 416.39 | >500 | >500 | ||
| 4h | 12.79 | >500 | >500 | >500 | >500 | ||
| 4i | >500 | >500 | >500 | >500 | >500 | ||
| 4j | >500 | >500 | 5.73 | 367.33 | >500 | ||
| 4k | >500 | >500 | >500 | >500 | >500 | ||
| 4l | >500 | >500 | 359.35 | 359.35 | >500 | ||
| 4m | >500 | 381.36 | 190.68 | 381.36 | >500 | ||
| 4n | >500 | 379.37 | 5.92 | 379.37 | >500 | ||
| 4o | 329.31 | 329.32 | 10.29 | 82.33 | >500 | ||
| 4p | 371.39 | >500 | 2.96 | >500 | >500 | ||
| 5a | 305.33 | >500 | 9.5 | >500 | >500 | ||
| 5b | 510.54 | 510.54 | 3.9 | >500 | >500 | ||
| 5c | 297.35 | 297.32 | 2.32 | 297.32 | 297.32 | ||
| 5d | >500 | 295.29 | 73.82 | >500 | >500 | ||
| 5e | >500 | >500 | >500 | >500 | >500 | ||
| 5f | 159.68 | >500 | >500 | >500 | >500 | ||
| 5j | 161.66 | >500 | 161.66 | >500 | >500 | ||
| 5k | >500 | >500 | >500 | >500 | >500 | ||
| 5l | >500 | >500 | 78.83 | 315.34 | 315.34 | ||
| 5o | 335.36 | >500 | 167.68 | >500 | 500> | ||
| Cefixime | 4 | 32 | 1 | 32 | - | ||
| Ciprofloxacin | 0.5 | 64 | 0.25 | 64 | - | ||
| Nystatin | - | - | - | - | 64 | ||
E. coli PTCC 1399; A. baumannii, clinical isolate; S. aureus PTCC 1431; MRSA, clinical isolate; C. albicans ATCC 10231.